Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)

Fineline Cube Jul 27, 2022

China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review

Fineline Cube Jul 27, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...

Company Deals

CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment

Fineline Cube Jul 27, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...

Company Deals

Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal

Fineline Cube Jul 27, 2022

China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun...

Company Drug

Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1

Fineline Cube Jul 27, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab...

Company Deals

CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease

Fineline Cube Jul 27, 2022

China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...

Company Deals R&D

HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration

Fineline Cube Jul 27, 2022

China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging...

Company Deals

Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing

Fineline Cube Jul 27, 2022

Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic...

Company Deals

Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences

Fineline Cube Jul 27, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer...

Company Deals

Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development

Fineline Cube Jul 27, 2022

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a...

Company Drug

Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer

Fineline Cube Jul 27, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Deals

Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal

Fineline Cube Jul 26, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme...

Company Drug

SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval

Fineline Cube Jul 26, 2022

SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus...

Company Deals

Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development

Fineline Cube Jul 26, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell...

Company Medical Device

AbbVie’s Allergan Aesthetics CoolAdvantage Applicator Wins NMPA Approval

Fineline Cube Jul 26, 2022

US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical...

Company Drug

Henlius Biotech’s Hanquyou Approved in Australia for HER2-Positive Cancers

Fineline Cube Jul 26, 2022

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s...

Company Drug

Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study

Fineline Cube Jul 26, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Drug

Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors

Fineline Cube Jul 26, 2022

China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a...

Company Drug

Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study

Fineline Cube Jul 26, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Deals

Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma

Fineline Cube Jul 26, 2022

China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...

Posts pagination

1 … 588 589 590 … 609

Recent updates

  • J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
  • Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.